You are viewing a single comment's thread from:

RE: LeoThread 2025-01-03 09:38

in LeoFinance20 days ago

Part 3/7:

Comparing Cassava and AVXL

Cassava Sciences, another player in the Alzheimer's space, has had its own share of volatility and mixed reactions from the market. Discussions often reveal the similarities between AVXL and Cassava—not merely in their therapeutic targets, but also in how their data is presented and perceived by investors. The emphasis on clinical performance, particularly during trial phases, has made Cassava a contentious stock to analyze; some investors remain hopeful following positive data iterations while others express caution.